Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
T cell receptor alpha variable 3 (TRAV3) is one of many variable (V) gene segments in the TCR alpha locus. During T cell development in the thymus, TRAV3 and other V segments are recombined with J (joining) gene segments to form the variable region of the T cell receptor alpha chain. This enables the generation of diverse TCRs, each recognizing a specific peptide antigen presented by MHC molecules on antigen-presenting cells. The TRAV3 segment supplies sequence diversity to the TCR repertoire and, together with its paired beta chain, determines antigen specificity and T cell function. While variable gene usage such as TRAV3 is fundamental for adaptive immunity, individual TRAV segments are not themselves considered independent therapeutic targets or disease biomarkers—they constitute modular elements of the TCR receptor on the surface of T lymphocytes[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on T cell receptor alpha variable 3 (TRAV3).